Although the incidence of pneumonia-related symptoms was higher in PD-1 or PD-L1 treatment group, the difference in pneumonia (RR: 0.96, 95% CI: 0.79–1.18) between two groups was not significant, as is shown in Figure S3. Here, RPL17 is linked to susceptibility to pneumonia measurement.